dioscin has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ajouaoi, S; Ben Mrid, R; Bouargalne, Y; Bouchmaa, N; Cacciola, F; El Fatimy, R; Nhiri, M; Zyad, A | 1 |
1 other study(ies) available for dioscin and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
In vitro evaluation of dioscin and protodioscin against ER-positive and triple-negative breast cancer.
Topics: Antineoplastic Agents; Antioxidants; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Endoplasmic Reticulum; Female; Humans; Hydrogen Peroxide; Leukocytes, Mononuclear; Triple Negative Breast Neoplasms | 2023 |